FDA Warns On Possible Heart, Diabetes Risk With Prostate Cancer Drugs Including Abbott Laboratories (ABT)' Lupron, AstraZeneca PLC (AZN)'s Zoladex, Sanofi-Aventis (France) (SASY.PA)'s Eligard, and Pfizer Inc. (PFE)'s Synarel  
10/21/2010 6:33:59 AM

Wall Street Journal -- WASHINGTON (Dow Jones)--New warnings about the potential risk of cardiovascular problems and diabetes will be added to the labels of hormone-therapy drugs that are used to treat prostate cancer, the Food and Drug Administration said Wednesday.